Clinical Trials Logo

Amyotrophic Lateral Sclerosis clinical trials

View clinical trials related to Amyotrophic Lateral Sclerosis.

Filter by:
  • No longer available  
  • Page 1

NCT ID: NCT05597436 No longer available - Clinical trials for Amyotrophic Lateral Sclerosis

Intermediate-Sized Expanded Access Study

Start date: n/a
Phase:
Study type: Expanded Access

This expanded access protocol is to provide access to the investigational product, SLS-005, to participants with ALS who are not eligible to participate in clinical trials.

NCT ID: NCT04681118 No longer available - Clinical trials for Amyotrophic Lateral Sclerosis

Expanded Access Protocol: Repeated Administration of Nurown® (Autologous MSC-NTF Cells) for the Treatment of ALS

Start date: n/a
Phase:
Study type: Expanded Access

Expanded Access for treatment with investigational product MSC-NTF cells(NurOwn®) for participants who completed all scheduled treatments and follow-up assessments in the BCT-002-US study

NCT ID: NCT04514952 No longer available - Clinical trials for Amyotrophic Lateral Sclerosis

Individual Patient Expanded Access IND of Autologous HBadMSCs for the Treatment of Amyotrophic Lateral Sclerosis

Start date: n/a
Phase:
Study type: Expanded Access

The drug for this submission is Hope Biosciences' autologous, adipose-derived culture-expanded mesenchymal stem cells (HB-adMSCs) for the treatment of a single patient with Amyotrophic Lateral Sclerosis (ALS). Stem cells have become a promising tool for the treatment of inflammatory and neurodegenerative conditions, including autoimmune diseases, traumatic brain injury, Parkinson's disease, and Alzheimer's disease.

NCT ID: NCT04309604 No longer available - Clinical trials for Amyotrophic Lateral Sclerosis

IC14 for ALS Patients Expanded Access

EAP
Start date: n/a
Phase:
Study type: Expanded Access

The primary objective is to provide the investigational product, IC14, at the dose of 8 mg/kg intravenously every 2 weeks for 12 weeks to 6 participants with amyotrophic lateral sclerosis (ALS). No clinical hypotheses are being tested. An extension for 6 additional doses every 2 weeks will be allowed if the drug is safe and well tolerated.A second extension for 14 doses every 2 weeks will be allowed if the drug is safe and well tolerated.

NCT ID: NCT03537807 No longer available - Clinical trials for Amyotrophic Lateral Sclerosis

Expanded Access Protocol of BHV-0223 for Patients With Amyotrophic Lateral Sclerosis (ALS)

Start date: n/a
Phase:
Study type: Expanded Access

This is an open label expanded access protocol for the treatment of up to approximately 250 adult patients with amyotrophic lateral sclerosis (ALS) who have difficulty swallowing oral riluzole tablets and may be able to derive benefit from treatment with an alternative oral formulation of riluzole.